Close Menu

NEW YORK – In a new study published in JAMA Network Open, researchers have analyzed genomic, transcriptomic, and immune profiles of patients who participated in a Phase II clinical trial and associated their immune functional states with distinct classes of long noncoding RNA (lncRNA). They found that these classes appeared to be predictive of the patients' immunotherapy outcomes.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.